ClinicalThought™: Hepatitis Highlights

Sunday, March 3, 2013

ClinicalThought™: Hepatitis Highlights

When education-related information on hepatitis C becomes available this blog points the reader to the new learning activity. Last month over at CCO a new module became available highlighting viral hepatitis.

CCO provides online interactive, and live continuing medical education (CME) programs designed especially for healthcare providers. However, hepatitis C patients taking part in these open CME programs can tap into new data and acquire additional knowledge on HCV, the drugs undergoing clinical trials or those currently in clinical practice.

Requires free registration

ClinicalThought™: Hepatitis Highlights

Topics

• Hepatitis C: Screening Recommendations
• Hepatitis C: Deciding Whether to Biopsy
• Reducing HCV Mortality
• Use of IL28B in the Setting of HCV DAAs
• Impact of Setbacks in HCV Drug Development
• Management of Acute HCV Infection
• HCV PIs in Active Drug Users
• Use of HCV PIs in HCV/HIV Coinfection
• Anemia Management During HCV PI Therapy
• Eltrombopag for Thrombocytopenia in HCV-Infected Patients
• Hepatitis C: Clinical Trial Development
• Management of Hepatitis B

Source - http://www.clinicaloptions.com/Hepatitis.aspx

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Contact hcvnewdrugs@gmail.com

Helpful Links
HCV Education
Research Articles
Fibrosis
Cirrhosis
Liver Cancer
Liver Transplants
Fatty Liver Disease
HCV-elderly
Possible Side Effects Of HCV Therapy
Other Conditions Related To HCV
HCV Genotypes/treatment
HCV Newsletters
Premier Hepatitis C Websites

The above links offer data about interferon-free regimens approved to treat HCV, with learning activities, editorials, and tips from patient bloggers who understand the ups and downs of liver disease, in addition to a list of outstanding hepatitis C websites, blogs and support forums.

On Twitter
I highly suggest you follow Henry E. Chang on Twitter if you are interested in reading articles about the treatment and management of hepatitis C.

The controversy over expensive new drugs for hepatitis C
Link to research and news articles addressing the high cost of hepatitis C drugs; insurance restrictions - private insurers/Medicaid - and availability of generic versions/India, Egypt and other lower-income countries or through online "buyers clubs"

Latest Update Feb 12, 2019

Lancet Study:

Direct-acting antivirals reduce risk of premature mortality and liver cancer for people with chronic hepatitis C

These findings firmly counter those of a Cochrane review of direct-acting antiviral treatment trials that could neither confirm nor reject if direct-acting antivirals had an effect on long-term HCV-related morbidity and mortality. They also provide the best evidence to date to support guidance documents that recommend direct-acting antiviral treatment for all patients with chronic HCV infection.

The Controversy
Rebuttal over Cochrane Review of DAAs
A systematic review published by the Cochrane Collaboration suggested achieving SVR (cure) for patients using hepatitis C direct-acting antivirals (DAAs) doesn't correlate with any long term benefits. View each rebuttal and all ongoing media coverage.